Shandong Anshun Pharmaceutical Invests RMB 250 Million to Build Peptide Fermentation Production Lines
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
▲August 15-16NDC2024Biopharmaceutical Innovators Summit
Scan to register
Recently, the industrialization project of recombinant protein drugs by Shandong Anshun Pharmaceutical Co., Ltd. was disclosed on relevant websites.
Project Basic Information
Project Name: Industrialization Project of Recombinant Protein Drugs by Shandong Anshun Pharmaceutical Co., Ltd.
Construction Unit: Shandong Anshun Pharmaceutical Co., Ltd.
Construction Location: North Area of Shandong Anshun Pharmaceutical Co., Ltd., Leling Chemical Industry Park, Dezhou City, Shandong Province
The total investment of the project is 250 million yuan, mainly constructing a 1910 workshop and fully utilizing the existing plant of the 1100 workshop for renovation. Additional supporting equipment and facilities will be added to build two polypeptide fermentation production lines, reaching an annual production scale of 3,400 kg of QL2008, 100 kg of QL2010, and 1,500 kg of QL2201.。
Shandong Anshun Pharmaceutical Co., Ltd.Affiliated with Qilu Pharmaceutical Group, investing billions in Leling to build the Qilu Pharmaceutical (Leling) Medicine Industrial Park.
Covering an area of 2,800 mu, it mainly focuses on the R&D and production of high-end medical drugs for anti-infectives, anti-tumor agents, rare diseases, etc. Phase I: High-end medical API project for anti-infectives with an investment of 1.5 billion yuan has been put into operation; Phase II: Generic drugs and anti-tumor high-end medical API project with an investment of 1.9 billion yuan has been put into operation; Phase III: High-end drug R&D and production project with an investment of 2.32 billion yuan has been put into operation; Phase IV: Construction of R&D projects for peptide recombinant protein drugs such as Semaglutide.
Source: Public Information, Dezhou News Network
Copyright statement: This article is reproduced from the API Intelligence Bureau,Media or individuals who do not wish to be reproduced can contact us, and we will delete it immediately.
August 15Hall C, Booth C102 New Drug Founders Summit
Agenda
09:00-09:20 How to Navigate the Complex Environment of the Biopharmaceutical Industry(Subject to the actual meeting)
Wang Xingli｜Fosun Pharma, Executive President & Co-CEO of Innovative Drug Division
09:20-09:40 What Opportunities Can Chinese Biotech Companies Seize Under Pressure Across Cycles?
Cai Xuejun｜Former BMS, Global R&D Vice President
09:40-10:00 The Unavoidable Commercialization: How Should Biotech Companies View Commercialization?(Tentative, subject to the actual meeting)
Liu Qian｜AstraZeneca China, Vice President
10:00-10:20 How Qilu Pharmaceutical Co., Ltd. Responds to the Complex Biopharmaceutical Industry Environment
Qilu Pharmaceutical(Guest itinerary to be confirmed)
10:20-10:40 How Huadong Medicine Addresses the Complex Biopharmaceutical Industry Environment
Huadong Medicine(Guest itinerary to be confirmed)
10:40-11:00 Release of the 2024 Comprehensive Strength Rankings Series for Pharmaceutical Enterprises in China
Wang Zhongjian｜Yaorong Cloud, CTO & Vice General Manager
11:00-11:20 Boehringer Ingelheim's R&D Strategy and Project Requirements
Boehringer Ingelheim External Innovation Cooperation Center(Guest itinerary to be confirmed)
11:20-11:40 Insights into the Future: What Opportunities Remain for the Development of China's Biomedical Industry?(Subject to the actual event)
Mao Hua |Sullivan, Greater China Partner and Managing Director
11:40-12:20 Roundtable: What Are the Future Breakthroughs for China's Biotech Companies?
Jin Fang｜Healthcare, Chief Scientist
Deng Yongqi｜Kaif Pharma, CEO
Hengrui Medicine(Guest itinerary to be confirmed)
12:00-13:30 Lunch
[Rational Development Direction of New Drugs in China]
Forum Planner & Host:
Dang Qun, Real Biotech, President
13:30-13:55 Is FIC or BIC the better choice for innovative drugs? Addressing unmet clinical needs is key!
Party and Mass｜Real Biotech, President
13:55-14:20 Advances in the Development of FGFR Inhibitors by Abbisko Therapeutics
Chen Zhui｜And誉 Medicine, Co-founder and CSO
14:20-14:45 Efficacy Evaluation of Cell Therapy Products in Animals
Cao Baohong｜MediCore, Vice President of Pharmacology Department
14:45-15:10 Development of YAP/TEAD Inhibitors
Zhu Jidong｜Yituo Medicine, CEO
15:10-15:35 A Brief Discussion on the "Prodrug" Past and Present - Prodrug Research and Development at Changcheng Pharmaceuticals
Song Qinhui｜Changcheng Pharmaceutical, CMO
15:35-16:00 Research and Development of Innovative Drugs for Functional Cure of Chronic Hepatitis B
Zhang Chi |Xi'an Xintong Pharmaceuticals, Vice General Manager
16:00-16:25 Delivery of Excellence - Delivery-Guided Drug Innovation
Shen Wang｜Vivory Biotech, Founder, Chairman and CEO
Scan the code to register for the conference
[About PharmaCircle]
PharmCube PRHub aims to assist biopharmaceutical technology enterprises in brand promotion and business development services. It provides systematic solutions based on clients' real needs, making brand information easily understandable to the public through "translation-simplification-contextualization." With access to over 1 million vertical users across various channels, it achieves cooperation goals while helping partners complete a closed-loop marketing service from branding to business development. We have successfully organized dozens of offline biopharmaceutical R&D conferences with 1,000 attendees, covering fields such as small-molecule new drugs, large-molecule new drugs, improved new drugs, and cross-border BD transactions, serving more than a hundred listed/unicorn/biotech/pharmaceutical companies.
